Log In
BCIQ
Print this Print this
 

Biosimilar rituximab (RTXM83)

  Manage Alerts
Collapse Summary General Information
Company Chemo Group
DescriptionBiosimilar of rituximab, a chimeric mAb against CD20 antigen
Molecular Target CD20
Mechanism of ActionBinds CD20; Antibody; Biosimilar
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat non-Hodgkin's lymphoma (NHL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today